title: Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
abstract: This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC). Patients were randomised to receive oral FT 750 mg/m2/day for 21 days and LV 15 mg/m2 every 8 h in cycles repeated every 28 days (n=114), or intravenous LV 20 mg/m2 followed by 5-FU 425 mg/m2 daily for 5 days every 4 weeks for 2 cycles, and later every 5 weeks (n=123). Response rate was significantly higher in the FT/LV arm (27%, 95% CI 19-35) than in the 5-FU/LV arm (13%, 95% CI 7-19) (p<0.004). The median time to progression was 5.9 months (95% CI, 5.3-6.5; FT/LV arm) and 6.2 months (95% CI, 5.4-6.9; 5-FU/LV arm). Median overall survival was 12.4 months (95% CI, 10.3-14.5 months; FT/LV arm) and 12.2 months (95% CI, 8.9-15.7 months; 5-FU/LV arm) (p=n.s.; hazard ratio FT/LV:5-FU/LV=1.02). 5-FU/LV showed a higher incidence of grade 3/4 neutropenia (4.1 vs. 0%). Non-hematological toxicities showed similar incidences in the two treatment arms. Oral FT/LV was more active than IV 5-FU/LV in terms of objective response rate with similar overall survival, and with a favorable toxicity profile. This makes FT/LV a valid alternative to the IV 5-FU schedule in CRC patients.
authors.affiliation: Consorci Hospitalari Parc Taulí, Parc Taulí, Servei d'Oncologia Médica, s/n 08208 Sabadell, Barcelona, Spain. mnogue@hgv.es
authors.forename: Miquel
authors.initials: M
authors.lastname: Nogué
authors.forename: Antonieta
authors.initials: A
authors.lastname: Salud
authors.forename: Eduard
authors.initials: E
authors.lastname: Batiste-Alentorn
authors.forename: Eugeni
authors.initials: E
authors.lastname: Saigí
authors.forename: Ferran
authors.initials: F
authors.lastname: Losa
authors.forename: Lluís
authors.initials: L
authors.lastname: Cirera
authors.forename: Miguel
authors.initials: M
authors.lastname: Méndez
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Campos
authors.forename: Antonio
authors.initials: A
authors.lastname: Galan
authors.forename: Pilar
authors.initials: P
authors.lastname: Escudero
authors.forename: Angels
authors.initials: A
authors.lastname: Arcusa
authors.forename: Hermini
authors.initials: H
authors.lastname: Manzano
authors.forename: Edelmira Vélez
authors.initials: EV
authors.lastname: de Mendizábal
authors.forename: Joaquim Pérez
authors.initials: JP
authors.lastname: de Olaguer
authors.forename: Montserrat
authors.initials: M
authors.lastname: Boleda
authors.forename: Immaculada
authors.initials: I
authors.lastname: Guasch
authors.forename: Pilar
authors.initials: P
authors.lastname: Vicente
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005641:Tegafur; D002955:Leucovorin; D005472:Fluorouracil